[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Research Letter
May 2017

Review of the Drug Trials Snapshots Program of the US Food and Drug Administration: Women in Cardiovascular Drug Trials

Author Affiliations
  • 1Professional Affairs and Stakeholder Engagement, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland
  • 2US Food and Drug Administration, Silver Spring, Maryland
JAMA Intern Med. 2017;177(5):724-727. doi:10.1001/jamainternmed.2017.0033

Over the last 20 years, there have been concerns that too few women and minorities are enrolled in clinical trials to provide confidence about drug safety and effectiveness. Women’s advocacy groups, in particular, have called for more representation in trials of cardiovascular diseases. In 2012, the US Food and Drug Administration (FDA) Safety and Innovation Act (FDASIA 907) was enacted and required the FDA to report on the diversity of participants in clinical trials and the extent to which safety and effectiveness data are based on demographic factors such as sex, race, and age. In response, the FDA piloted a new transparency initiative called the Drug Trials Snapshots Program. Snapshots are data posted online in a standardized format after approval of a “new molecular entity” (NME). They show who participated in the pivotal clinical trials used to approve the drug by sex, race, and age subgroups. Snapshots also provide statements on observed demographic subgroup differences in safety and efficacy. The FDA releases a Snapshot for every NME approved after January 2015 within 30 days of the approval date.